Sangui BioTech Int'l, Inc.: Presentation of Manufacturing Recipe of the Artificial Oxygen Carrier Before International Experts at the ISOTT 'International Society on Oxygen Transport to Tissue' Meeting in Nijmegen.

Business Editors/Health and Medical Writers

ISOTT 2000

SANTA ANA, Calif.--(BW HealthWire)--Aug. 29, 2000

Sangui BioTech International Inc. (NASDAQ BB: SGBI; WKN 906 757; SBH.GR (Bloomberg), SGBI.H (Reuters)) announced today that its subsidiary SanguiBioTech AG, Witten, Germany, presented at the ISOTT 2000 Meeting in Nijmegen, Netherlands (August 20-24, 2000) the newly developed manufacturing recipe of the artificial oxygen carrier as well as the physical specifications of the carriers obtained by it to a group of experts active in the field of "oxygen transport and oxygen transport to tissue." SanguiBioTech AG recently submitted patent applications at the German Patent Office, Munchen, concerning this manufacturing recipe.

SanguiBioTech AG has been developing artificial oxygen carriers on the basis of porcine hemoglobin. The enterprise employs a concept realized in nature in the earthworm; it develops what is called "hyper-polymers." These are giant molecules of a major number of linked hemoglobin units.

The development of an oxygen transporting additive that is added to the blood in case of a manifestation of lack of oxygen, such as cardiac infarction or cerebral apoplexy or in the tumor oxygenation, previously represented the basic concept of SanguiBioTech AG's research. In the course of the development work, however, it became clear that the manufacturing recipe not only allows the isolation of this high molecular oxygen transporting additive, but that it is also possible to obtain a low molecular blood volume substitute. This substitute could be used in the place of a unit of stored blood; for instance, in the case of an operation or after accidents.

Under the current laboratory conditions, when producing the carriers, in relation to "additive" and "substitute" a yield of nearly 80 percent is achieved, which is to be regarded as very high, in relation to the raw material. This high yield is also due to the "One-Chamber-Reaction" developed in the course of which initially all reaction steps necessary for the preparation of the carrier are effected in one container.

"With the new manufacturing process it is possible to manufacture with a very high yield artificial oxygen carriers with good functional properties for both types of applications simultaneously," said Professor Wolfgang Barnikol, MD, PhD, Chief Executive Officer of SanguiBioTech AG and Chief Executive Officer/President of Sangui BioTech International Inc., Santa Ana, California.

Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, technical development risks, seasonal and other risk factors detailed in the Company's SEC filings.